The acquisition reflects Johnson & Johnson’s push to strengthen its position in antibody engineering and next-generation oncology modalities
This alliance, covering up to 12 antibody drugs, highlights the growing trend of large-scale collaborations between Chinese biotech firms and global pharmaceutical giants
The company is also highlighting early-stage innovation in antibody-drug conjugates and in vivo CAR-T therapy
Tecentriq SC reduces treatment administration time by nearly 80 percent and has the potential to lower indirect treatment costs
As per GlobalData, CARsgen’s satri-cel could mark a major breakthrough in solid tumor treatment as competition intensifies
Selvax, founded in 1987, is focused on developing novel immunotherapy solutions with applications in both human and veterinary oncology
Former Interim CEO takes charge to drive strategic growth, strengthen clinical excellence, and advance patient-centric oncology innovation
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
